托法替布治疗溃疡性结肠炎的有效性与安全性:ICC登记研究两年结果
本研究基于荷兰全国性观察性ICC登记研究,前瞻性评估托法替布治疗溃疡性结肠炎患者长达24个月的有效性与安全性。纳入110例患者(94.5%有抗TNF暴露史),104周时31.8%达无激素临床缓解,23.4%达生化缓解,18.7%达临床与生化联合缓解。55.5%的患者中位13周停药,主要原因为无应答、失去应答和不良事件。
要点
- 104周时31.8%(34/107)达无激素临床缓解,23.4%(25/107)达生化缓解。
- 52周达无激素临床缓解者中76.5%(26/34)在104周时仍维持缓解。
- 55.5%(61例)停药,中位停药时间13周,主要因无应答、失去应答和不良事件。
核心结论
- 托法替布治疗24个月后,31.8%的患者仍有效。
研究设计与样本
- ICC登记研究为全国性观察性登记研究,纳入起始托法替布治疗的溃疡性结肠炎患者,前瞻性评估长达24个月。
- 共纳入110例患者,其中104例(94.5%)有抗TNF治疗经历。
主要发现
- 治疗104周时,31.8%(34/107)达无激素临床缓解(SCCAI≤2),23.4%(25/107)达生化缓解(CRP≤5 mg/L且FC≤250 μg/g),18.7%(20/107)达临床与生化联合缓解。
- 第52周达无激素临床缓解的患者中,76.5%(26/34)在104周时仍维持缓解。
- 61例(55.5%)停用托法替布,中位停药时间13周(IQR 7-34),停药主要原因包括无应答(59%)、失去应答(14.8%)和不良事件(18%)。
- 随访期间可能由托法替布相关的不良事件为每100患者年33.9例,最可能与托法替布相关的不良事件为皮肤反应和头痛。
- 带状疱疹感染为每100患者年6.4例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tofacitinib is an oral Janus kinase (JAK) inhibitor and is registered for the treatment of ulcerative colitis (UC). The effectiveness of tofacitinib has been evaluated up to 12 months of treatment. AIM: The aim of this study was to assess the effectiveness and safety of 24 months of tofacitinib use in UC patients in the Netherlands. METHODS: Patients initiating tofacitinib treatment were included in the ICC Registry, a nationwide, observational registry. Patients were prospectively evaluated for up to 24 months. The primary outcome was corticosteroid-free clinical remission (CSFR, Simple Clinical Colitis Activity Index [SCCAI] ≤2) at week 104. Secondary outcomes included biochemical remission (C-reactive protein (CRP) ≤5 mg/L and faecal calprotectin (FC) ≤250 μg/g), safety, and discontinuation rate. RESULTS: We included 110 patients of whom 104 (94.5%) were anti-TNF experienced. After 104 weeks of tofacitinib, 31.8% (34/107) were in CSFR, 23.4% (25/107) in biochemical remission and 18.7% (20/107) in combined clinical and biochemical remission. Of the patients in CSFR at week 52, 76.5% (26/34) remained so after 104 weeks of treatment. Sixty-one patients (55.5%) discontinued tofacitinib after a median duration of 13 weeks (IQR 7-34). The main reasons for discontinuation were non-response (59%), loss of response (14.8%), and adverse events (18%). There were 33.9 possible tofacitinib-related adverse events per 100 patient-years during follow-up. Adverse events most probably related to tofacitinib were skin reactions and headaches. There were 6.4 herpes zoster infections per 100 patient-years. CONCLUSION: Tofacitinib was effective in 31.8% of patients after 24 months of treatment. [Image: see text]Effectiveness and safety of tofacitinib for ulcerative colitis: Two‐year results of the ICC Registry
引用
- Straatmijer T, van Schaik FDM, Bodelier AGL, et al. Effectiveness and safety of tofacitinib for ulcerative colitis: two-year results of the ICC Registry. Aliment Pharmacol Ther. 2022. PMID: 36282200. doi:10.1111/apt.17248
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。